Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Celecoxib + escitalopram is a combination of two pharmaceutical drugs, each with distinct mechanisms of action. Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor classified as a nonsteroidal anti-inflammatory drug (NSAID), primarily used to treat pain and inflammation in conditions such as osteoarthritis and rheumatoid arthritis. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of major depressive disorder, generalized anxiety disorder, and other psychiatric conditions. The combination has been studied for potential synergistic effects in treating depression, particularly major depressive disorder; some evidence suggests that adding celecoxib to escitalopram may improve depressive symptoms without significantly increasing adverse events[3]. However, this combination carries an increased risk of bleeding due to additive effects on platelet function[1][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on celecoxib + escitalopram.